期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 1, 页码 388-409出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b01562
关键词
-
资金
- Australian Research Council [DP110100687]
- National Health and Medicinal Research Council (NHMRC) of Australia [APP1055134, APP1049564]
Positive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (M1 mAChR) are a promising strategy for the treatment of the cognitive deficits associated with diseases including Alzheimers and schizophrenia. Herein, we report the design, synthesis, and characterization of a novel family of M-1 mAChR PAMs. The most active compounds of the 4-phenylpyridin-2-one series exhibited comparable binding affinity to the reference compound, 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA) (1), but markedly improved positive cooperativity with acetylcholine, and retained exquisite selectivity for the M1 mAChR. Furthermore, our pharmacological characterization revealed ligands with a diverse range of activities, including modulators that displayed both high intrinsic efficacy and PAM activity, those that showed no detectable agonism but robust PAM activity and ligands that displayed robust allosteric agonism but little modulatory activity. Thus, the 4-phenylpyridin-2-one scaffold offers an attractive starting point for further lead optimization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据